Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Professor Laufs heads a research group focused on cellular and molecular mechanisms, and clinical studies of cardiovascular prevention with a special interest in lipid disorders. Additional research interests of the department include heart failure and cardiomyopathies, cardiac imaging, interventional cardiology and atrial fibrillation. He has > 550 publications listed medline that have been cited >38,000 times.
Teilstationäre Versorgung in universitären Kliniken für Kardiologie
Novel Long Noncoding RNA <i>HEAT4</i> Affects Monocyte Subtypes, Reducing Inflammation and Promoting Vascular Healing
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism—the Find-AF 2 study—rationale and design
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
Gene Therapy Targeting PCSK9
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Attenuation of the Heartbeat-Evoked Potential in Patients With Atrial Fibrillation
Sacubitril/Valsartan in Heart Failure: Efficacy and Safety in and Outside Clinical Trials
Travelling with heart failure: risk assessment and practical recommendations
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial
Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
The Evidence for Pharmacist Care in Outpatients with Heart Failure: A Systematic Review and Meta-Analysis
Hospitalizations for Heart Failure: Still Major Differences Between East and West Germany 30 Years After Reunification
SLM2 Is a Novel Cardiac Splicing Factor Involved in Heart Failure due to Dilated Cardiomyopathy
Expert opinion paper on cardiac imaging after ischemic stroke
Inhibition of Rac1 GTPase Decreases Vascular Oxidative Stress, Improves Endothelial Function, and Attenuates Atherosclerosis Development in Mice
Long-Term Follow-up of Enhanced Holter-Electrocardiography Monitoring in Acute Ischemic Stroke
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
The Impact of Pharmacist/Physician Care on Quality of Life in Elderly Heart Failure Patients: Results of the PHARM-CHF Randomized Controlled Trial